Summary

The global bioinformatics market is projected to reach USD 34.41 billion by 2031, up from USD 18.63 billion in 2026, at a CAGR of 13.1% over the forecast period. Rapid growth in genomics research, precision medicine initiatives, and drug discovery programs has significantly increased demand for bioinformatics platforms that store, manage, analyze, and interpret complex biological datasets. Pharmaceutical and biotechnology companies, academic institutions, and healthcare organizations are increasingly adopting integrated bioinformatics solutions to accelerate research, improve clinical decision-making, and optimize therapeutic development. Furthermore, the growing digital transformation of life science research, coupled with rising investments in computational biology and cloud-based bioinformatics platforms, is improving workflow efficiency, enabling large-scale data sharing, and supporting collaborative research across organizations.

End-to-end solutions projected to be the largest software segment in the bioinformatics market
Software-based end-to-end solutions are expected to dominate market share during the forecast period. This dominance is driven by growing demand for integrated platforms that support complete bioinformatics workflows, including biological data acquisition, storage, processing, analysis, visualization, interpretation, and reporting. These comprehensive solutions enable researchers and clinicians to efficiently manage complex genomic, proteomic, transcriptomic, and multi-omics datasets through a single platform, reducing workflow complexity and improving operational efficiency. As the volume and complexity of biological data continue to increase, demand for scalable, integrated bioinformatics platforms is expected to further strengthen the leadership of the end-to-end solutions segment throughout the forecast period.

By sector, medical biotechnology accounted for the major share of the bioinformatics market
Within the sector, medical biotechnology accounted for the largest share, driven by the growing use of bioinformatics across genomics, precision medicine, molecular diagnostics, drug discovery, biomarker identification, and clinical research. The rising prevalence of chronic diseases, cancer, and rare genetic disorders has further accelerated the adoption of bioinformatics solutions to support personalized treatment strategies and advanced molecular diagnostics. In addition, ongoing advances in next-generation sequencing (NGS), artificial intelligence (AI), machine learning, and cloud-based bioinformatics platforms have improved the speed, scalability, and accuracy of biological data analysis. Increasing investments in life science research, precision medicine initiatives, and genomic medicine programs are expected to further reinforce the medical biotechnology segment's leading position throughout the forecast period.

Asia Pacific to witness the fastest growth rate during the forecast period.
The bioinformatics market in Asia Pacific is projected to have the highest CAGR during the forecast period, primarily driven by rising investments in genomics research, precision medicine, and biotechnology across emerging economies such as China, India, Japan, South Korea, and Singapore. Governments in the region are actively supporting genomics and life sciences research through funding initiatives, national genomics programs, and policies that promote digital healthcare and biotechnology innovation.

The break-down of primary participants is as mentioned below:
- By Company Type - Tier 1: 46%, Tier 2: 34%, and Tier 3: 20%
- By Designation - C-level: 35%, Director-level: 25%, and Others: 40%
- By Region - North America: 45%, Europe: 30%, Asia Pacific: 20%, Latin America: 3%, and Middle East & Africa: 2%.

Thermo Fisher Scientific Inc. (US) & Illumina, Inc. (US) are some of the key players in the bioinformatics market

- The study includes an in-depth competitive analysis of these key players in the bioinformatics market, with their company profiles, recent developments, and key market strategies.

Research Coverage
This research report categorizes the bioinformatics market by offerings (software & bioinformatics services), by function (data analysis, structural & functional analysis, multi-omics integration, clinical interpretation, data visualization & reporting, other functions), by use case (drug discovery & development, precision medicine, clinical diagnostics, biomarker discovery, research & academic applications, other use cases), by sector (medical biotechnology, animal biotechnology, plant biotechnology, environmental biotechnology, forensic biotechnology, other sectors), by end user (pharmaceutical & biotechnology companies, academic and research institutes, hospitals & clinical diagnostic laboratories, contract research organizations (CROs) & contract development and manufacturing organizations (CDMOs), government and public health organizations, other end users), and by region (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa). The scope of the report covers detailed information on the major factors, such as drivers, restraints, challenges, and opportunities, that influence the growth of the bioinformatics market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, key strategies, partnerships, agreements, product and service launches, mergers and acquisitions, and recent developments associated with the bioinformatics market. The report also covers a competitive analysis of upcoming startups in the bioinformatics market ecosystem.

Reasons to buy this report
The report will provide market leaders and new entrants with the closest approximations of revenue figures for the bioinformatics market and its subsegments. It will help stakeholders understand the competitive landscape and gain insights to position their businesses more effectively and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights into the following pointers:
- Analysis of key drivers (increasing adoption of next-generation sequencing (NGS), growing demand for personalized medicine, rising pharmaceutical and biotechnology R&D expenditure, increasing public and private-sector funding for bioinformatics, increasing adoption of AI and machine learning in the life sciences), restraints (high cost of bioinformatics infrastructure, data privacy, security, and regulatory compliance concerns, shortage of skilled bioinformatics professionals), opportunities (lucrative opportunities in emerging markets, expansion of clinical bioinformatics, adoption of cloud and federated bioinformatics platforms, growth of bioinformatics outsourcing services), and challenges (management of large data volumes, lack of interoperability and multiplatform capabilities, growing competition from in-house development and publicly available tools, integration of multi-omics datasets)
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the bioinformatics market
- Market Development: Comprehensive information about lucrative markets – the report analyzes the bioinformatics market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the bioinformatics market
- Competitive Assessment: In-depth assessment of market share, growth strategies, and product offerings of leading players such as Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), among others, in the bioinformatics market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 37
1.2 MARKET DEFINITION 37
1.3 STUDY SCOPE 38
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 38
1.3.2 INCLUSIONS & EXCLUSIONS 39
1.3.3 YEARS CONSIDERED 40
1.3.4 CURRENCY CONSIDERED 41
1.4 STAKEHOLDERS 41
1.5 SUMMARY OF CHANGES 41

2 EXECUTIVE SUMMARY 43
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 43
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 45
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 46
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 47
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 48

3 PREMIUM INSIGHTS 49
3.1 BIOINFORMATICS MARKET OVERVIEW 49
3.2 BIOINFORMATICS MARKET, BY OFFERING & REGION 50
3.3 BIOINFORMATICS MARKET: GEOGRAPHIC SNAPSHOT 50

4 MARKET OVERVIEW 51
4.1 INTRODUCTION 51
4.2 MARKET DYNAMICS 51
4.2.1 DRIVERS 52
4.2.1.1 Increasing adoption of next-generation sequencing (NGS) 52
4.2.1.2 Growing demand for personalized medicine 52
4.2.1.3 Increasing pharmaceutical and biotechnology R&D expenditure 54
4.2.1.4 Increasing public and private-sector funding for bioinformatics 55
4.2.1.5 Increasing adoption of AI and machine learning in life sciences 57
4.2.1.6 Decreasing cost of genome sequencing 58
4.2.2 RESTRAINTS 58
4.2.2.1 High cost of bioinformatics infrastructure 58
4.2.2.2 Data privacy, security, and regulatory compliance concerns 59
4.2.2.3 Shortage of skilled bioinformatics professionals 60
4.2.3 OPPORTUNITIES 60
4.2.3.1 Lucrative opportunities in emerging markets 60
4.2.3.2 Expansion of clinical bioinformatics 61
4.2.3.3 Adoption of cloud and federated bioinformatics platforms 61
4.2.3.4 Growth of bioinformatics outsourcing services 62
4.2.4 CHALLENGES 62
4.2.4.1 Management of large data volumes 62
4.2.4.2 Lack of interoperability and multiplatform capabilities 62
4.2.4.3 Growing competition from in-house development and publicly available tools 63
4.2.4.4 Integration of multiomics datasets 63
4.3 UNMET NEEDS AND WHITE SPACES 64
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 65
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 66

5 INDUSTRY TRENDS 68
5.1 PORTER’S FIVE FORCES ANALYSIS 68
5.1.1 THREAT OF NEW ENTRANTS 69
5.1.2 THREAT OF SUBSTITUTES 69
5.1.3 BARGAINING POWER OF SUPPLIERS 69
5.1.4 BARGAINING POWER OF BUYERS 69
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 70
5.2 MACROECONOMIC INDICATORS 70
5.2.1 INTRODUCTION 70
5.2.2 GDP TRENDS AND FORECAST 70
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 71
5.3 VALUE CHAIN ANALYSIS 71
5.3.1 RESEARCH & PRODUCT DEVELOPMENT 72
5.3.2 TECHNOLOGY INFRASTRUCTURE 72
5.3.3 PLATFORM DEVELOPMENT 72
5.3.4 DISTRIBUTION 72
5.3.5 MARKETING & SALES 73
5.3.6 POST-SALE SERVICES 73
5.4 ECOSYSTEM ANALYSIS 73
5.5 PRICING ANALYSIS 74
5.5.1 INDICATIVE PRICING FOR BIOINFORMATICS MARKET, BY OFFERING (2025) 75
5.5.2 INDICATIVE PRICING IN BIOINFORMATICS MARKET, BY REGION (2025) 75
5.6 KEY CONFERENCES AND EVENTS, 2026–2027 76
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 78
5.8 INVESTMENT AND FUNDING SCENARIO 79
5.9 CASE STUDY ANALYSIS 80
5.10 IMPACT OF 2025 US TARIFF –BIOINFORMATICS MARKET 82
5.10.1 INTRODUCTION 82
5.10.2 KEY TARIFF RATES 83
5.10.3 PRICE IMPACT ANALYSIS 84
5.10.4 IMPACT ON COUNTRY/REGION 84
5.10.4.1 US 84
5.10.4.2 Europe 85
5.10.4.3 Asia Pacific 85
5.10.5 IMPACT ON END USERS 85
5.10.5.1 Pharmaceutical & biotechnology companies 85
5.10.5.2 Academic & research institutes 86
5.10.5.3 Hospitals & clinical diagnostic laboratories 86
5.10.5.4 Contract research organizations and contract development & manufacturing organizations 86
5.10.5.5 Government & public health organizations 86

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 87
6.1 KEY EMERGING TECHNOLOGIES 87
6.1.1 NEXT-GENERATION SEQUENCING TECHNOLOGIES 87
6.1.2 ARTIFICIAL INTELLIGENCE & MACHINE LEARNING 88
6.1.3 MULTIOMICS ANALYSIS PLATFORMS 88
6.1.4 VARIANT INTERPRETATION & CLINICAL DECISION SUPPORT 88
6.2 COMPLEMENTARY TECHNOLOGIES 89
6.2.1 GENERATIVE AI FOR BIOINFORMATICS 89
6.2.2 AI-BASED DRUG DISCOVERY PLATFORMS 89
6.2.3 LARGE LANGUAGE MODELS FOR LIFE SCIENCES 89
6.3 ADJACENT TECHNOLOGIES 90
6.3.1 HIGH-PERFORMANCE COMPUTING 90
6.3.2 BIG DATA ANALYTICS 90
6.3.3 BLOCKCHAIN TECHNOLOGY 91
6.3.4 ROBOTICS & LABORATORY AUTOMATION 91
6.4 TECHNOLOGY/PRODUCT ROADMAP 91
6.5 PATENT ANALYSIS 92
6.5.1 PATENT PUBLICATION TRENDS FOR BIOINFORMATICS MARKET 92
6.5.2 BIOINFORMATICS PATENTS: JURISDICTION AND TOP APPLICANT ANALYSIS 93
6.6 FUTURE APPLICATIONS 96
6.6.1 AI-DRIVEN GENOMIC INTERPRETATION & CLINICAL DECISION SUPPORT 96
6.6.2 PRECISION MEDICINE & MULTIOMICS INTEGRATION 96
6.6.3 INTEGRATED BIOINFORMATICS FOR DRUG DISCOVERY & CLINICAL RESEARCH 96
6.7 IMPACT OF GEN AI IN BIOINFORMATICS MARKET 97
6.7.1 INTRODUCTION 97
6.7.2 MARKET POTENTIAL OF AI/GEN AI IN BIOINFORMATICS MARKET 98
6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 99
6.7.3.1 AI-powered genomics for precision medicine at Illumina and
Tempus AI 99
6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 100
6.7.4.1 AI in bioinformatics software market 100
6.7.4.2 Next-generation sequencing market 100
6.7.4.3 Drug discovery market 101
6.7.5 USERS READINESS AND IMPACT ASSESSMENT 101
6.7.5.1 User readiness 101
6.7.5.1.1 Pharmaceutical & biotechnology companies 101
6.7.5.1.2 Academic & research institutes 101
6.7.5.1.3 Hospitals & clinical diagnostic laboratories 101
6.7.5.1.4 Contract research organizations and contract development & manufacturing organizations 102
6.7.5.2 Impact assessment 102
6.7.5.2.1 User A: Pharmaceutical & biotechnology companies 102
6.7.5.2.1.1 Implementation 102
6.7.5.2.1.2 Impact 102
6.7.5.2.2 User B: Academic & Research Institutes 102
6.7.5.2.2.1 Implementation 102
6.7.5.2.2.2 Impact 103
6.7.5.2.3 User C: Hospitals & Clinical Diagnostic Laboratories 103
6.7.5.2.3.1 Implementation 103
6.7.5.2.3.2 Impact 103
6.7.5.2.4 User D: Contract research organizations and contract development & manufacturing organizations 103
6.7.5.2.4.1 Implementation 103
6.7.5.2.4.2 Impact 103

7 REGULATORY LANDSCAPE 104
7.1 REGIONAL REGULATIONS AND COMPLIANCE 104
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105
7.1.2 REGULATORY FRAMEWORK 108
7.1.2.1 North America 108
7.1.2.2 Europe 109
7.1.2.3 Asia Pacific 110
7.1.2.4 Latin America 110
7.1.2.5 Middle East & Africa 111
7.1.3 INDUSTRY STANDARDS 111

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 113
8.1 INTRODUCTION 113
8.2 DECISION-MAKING PROCESS 113
8.3 STAKEHOLDERS AND BUYING EVALUATION CRITERIA 113
8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 114
8.3.2 BUYING CRITERIA 115
8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES 116
8.5 UNMET NEEDS FROM VARIOUS END USERS 117
8.5.1 UNMET NEEDS 117
8.5.2 END USER EXPECTATIONS 119
8.6 MARKET PROFITABILITY 120

9 BIOINFORMATICS MARKET, BY OFFERING 121
9.1 INTRODUCTION 122
9.2 SOFTWARE 122
9.2.1 NICHE POINT SOLUTIONS 124
9.2.1.1 Increasing adoption of NGS and multiomics technologies to boost growth 124
9.2.2 KNOWLEDGE MANAGEMENT TOOLS 125
9.2.2.1 Rising demand for genomic variant interpretation databases 125
9.2.2.2 Generalized knowledge management tools 126
9.2.2.2.1 Development of novel generalized knowledge management tools to drive growth 126
9.2.2.3 Specialized knowledge management tools 127
9.2.2.3.1 Data security and highly reliable information storage systems to support growth 127
9.2.3 END-TO-END SOLUTIONS 129
9.2.3.1 Integration of artificial intelligence (AI) and machine learning (ML) to drive growth 129
9.2.3.2 Genomic solutions 130
9.2.3.2.1 Expansion of precision medicine and genomic diagnostics – segment driver 130
9.2.3.3 Multiomics solutions 132
9.2.3.3.1 Increasing integration of genomics, transcriptomics, proteomics, and metabolomics dataset to drive market 132
9.2.3.4 Chemoinformatics solutions 133
9.2.3.4.1 Increasing investment in R&D to boost segment 133
9.2.3.5 Proteomics solutions 135
9.2.3.5.1 Growing focus on protein biomarker discovery fuels adoption 135
9.2.3.6 Transcriptomics solutions 136
9.2.3.6.1 Rising demand for gene expression analysis accelerates adoption 136
9.2.3.7 Metabolomics solutions 137
9.2.3.7.1 Adoption of LC-MS and GC-MS technologies accelerates segment growth 137
9.2.3.8 Other end-to-end Solutions 138
9.3 SERVICES 139
9.3.1 SEQUENCING & DATA GENERATION 141
9.3.1.1 Increasing adoption of NGS drives demand 141
9.3.2 DATA ANALYSIS & INTERPRETATION 142
9.3.2.1 Growing complexity of multiomics data drives demand 142
9.3.3 DRUG DISCOVERY & TARGET IDENTIFICATION 143
9.3.3.1 Increasing adoption of precision medicine fuels demand 143
9.3.4 DATABASE & DATA MANAGEMENT 145
9.3.4.1 Exponential growth of biological data drives segment 145
9.3.5 CLOUD & MANAGED BIOINFORMATICS 146
9.3.5.1 Increasing adoption of cloud computing accelerates segment growth 146
9.3.6 CONSULTING & CUSTOM BIOINFORMATICS DEVELOPMENT 147
9.3.6.1 Increasing demand for customized bioinformatics workflows boosts segment 147
9.3.7 OTHER SERVICES 148

10 BIOINFORMATICS MARKET, BY FUNCTION 150
10.1 INTRODUCTION 151
10.2 DATA ANALYSIS 151
10.2.1 SEQUENCE ANALYSIS 153
10.2.1.1 Growing volume of sequencing data drives demand 153
10.2.2 VARIANT ANALYSIS 153
10.2.2.1 Increasing adoption of precision medicine to boost segment 153
10.2.3 GENE EXPRESSION ANALYSIS 154
10.2.3.1 Expanding transcriptomics research drives segment growth 154
10.2.4 OTHER DATA ANALYSIS FUNCTIONS 155
10.3 STRUCTURAL & FUNCTIONAL ANALYSIS 155
10.3.1 GROWING ADOPTION OF STRUCTURE-BASED DRUG DISCOVERY AND PROTEIN MODELING TO BOOST GROWTH 155
10.4 MULTIOMICS INTEGRATION 156
10.4.1 INCREASING INTEGRATION OF MULTIOMICS DATA DRIVES DEMAND FOR ADVANCED BIOINFORMATICS PLATFORMS 156
10.5 CLINICAL INTERPRETATION 157
10.5.1 GROWING ADOPTION OF PRECISION MEDICINE AND CLINICAL GENOMICS IS PROPELS GROWTH 157
10.6 DATA VISUALIZATION & REPORTING 158
10.6.1 INCREASING ADOPTION OF AI-DRIVEN DRUG DISCOVERY AND COMPUTATIONAL CHEMISTRY – KEY SEGMENT DRIVER 158
10.7 OTHER FUNCTIONS 159

11 BIOINFORMATICS MARKET, BY USE CASE 161
11.1 INTRODUCTION 162
11.2 DRUG DISCOVERY & DEVELOPMENT 162
11.2.1 GROWING PHARMACEUTICAL R&D INVESTMENTS DRIVE GROWTH 162
11.3 PRECISION MEDICINE 163
11.3.1 INCREASING DEMAND FOR PERSONALIZED TREATMENT STRATEGIES TO BOOST SEGMENT 163
11.4 CLINICAL DIAGNOSTICS 164
11.4.1 GROWING ADOPTION OF GENOMIC TESTING – KEY DRIVER 164
11.5 BIOMARKER DISCOVERY 165
11.5.1 GROWING FOCUS ON PRECISION MEDICINE AND COMPANION DIAGNOSTICS TO BOOST SEGMENT 165
11.6 RESEARCH & ACADEMIC APPLICATIONS 166
11.6.1 INCREASING INVESTMENTS IN LIFE SCIENCE RESEARCH PROPEL SEGMENT GROWTH 166
11.7 OTHER USE CASES 167

12 BIOINFORMATICS MARKET, BY SECTOR 169
12.1 INTRODUCTION 170
12.2 MEDICAL BIOTECHNOLOGY 170
12.2.1 EXPANSION OF GENOMIC DIAGNOSTICS, MOLECULAR TESTING, AND PERSONALIZED HEALTHCARE TO DRIVE SEGMENT 170
12.3 ANIMAL BIOTECHNOLOGY 171
12.3.1 INCREASING ADOPTION OF PRECISION LIVESTOCK FARMING AND VETERINARY GENOMICS TO PROPEL GROWTH 171
12.4 PLANT BIOTECHNOLOGY 172
12.4.1 GROWING DEMAND FOR CLIMATE-RESILIENT AND HIGH-YIELD CROPS TO BOOST SEGMENT 172
12.5 ENVIRONMENTAL BIOTECHNOLOGY 173
12.5.1 INCREASING ADOPTION OF ENVIRONMENTAL DNA (EDNA) AND METAGENOMICS BOOSTS GROWTH 173
12.6 FORENSIC BIOTECHNOLOGY 174
12.6.1 INCREASING ADOPTION OF NEXT-GENERATION SEQUENCING AND FORENSIC GENOMICS TO DRIVE SEGMENT 174
12.7 OTHER SECTORS 175

13 BIOINFORMATICS MARKET, BY END USER 177
13.1 INTRODUCTION 178
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 178
13.2.1 INCREASING PHARMACEUTICAL R&D INVESTMENTS
AND ADOPTION OF ADVANCED COMPUTATIONAL TECHNOLOGIES 178
13.3 ACADEMIC & RESEARCH INSTITUTES 180
13.3.1 GROWING GOVERNMENT FUNDING FOR BIOMEDICAL
RESEARCH DRIVES SEGMENT 180
13.4 HOSPITALS & CLINICAL DIAGNOSTIC LABORATORIES 181
13.4.1 INCREASED APPLICATIONS IN DISEASE DIAGNOSTICS AND TREATMENT TO DRIVE MARKET GROWTH 181
13.5 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS 182
13.5.1 INCREASING OUTSOURCING OF DRUG DEVELOPMENT AND GROWING DEMAND FOR SPECIALIZED COMPUTATIONAL EXPERTISE 182
13.6 GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS 183
13.6.1 INCREASING INVESTMENTS IN GENOMIC SURVEILLANCE AND PUBLIC HEALTH INFORMATICS 183
13.7 OTHER END USERS 184

14 BIOINFORMATICS MARKET, BY REGION 186
14.1 INTRODUCTION 187
14.2 NORTH AMERICA 187
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 188
14.2.2 US 194
14.2.2.1 Strong government support and rapid advances in genomics and AI drive market 194
14.2.3 CANADA 200
14.2.3.1 Increasing government investments in genomics and national bioinformatics infrastructure 200
14.3 EUROPE 206
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 206
14.3.2 GERMANY 212
14.3.2.1 Strong government investments in precision medicine and expanding AI-enabled bioinformatics research 212
14.3.3 UK 218
14.3.3.1 Strategic initiatives and funding for genomics research to support market growth 218
14.3.4 FRANCE 224
14.3.4.1 Market driven by national genomics programs and AI-enabled biomedical research 224
14.3.5 ITALY 229
14.3.5.1 Favorable funding scenario to drive adoption of advanced sequencing technology 229
14.3.6 SPAIN 235
14.3.6.1 Growing focus on advancements in personalized medicine to support market growth 235
14.3.7 REST OF EUROPE 240
14.4 ASIA PACIFIC 245
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 246
14.4.2 CHINA 252
14.4.2.1 Expansion of national genomic data infrastructure drives market 252
14.4.3 JAPAN 257
14.4.3.1 Rising number of collaborations in bioinformatics to drive market 257
14.4.4 INDIA 263
14.4.4.1 Government and private initiatives for genomics projects to propel market 263
14.4.5 AUSTRALIA 268
14.4.5.1 Increased genetic research to support market growth 268
14.4.6 SOUTH KOREA 273
14.4.6.1 National biomedical data integration and AI-driven precision medicine accelerate market 273
14.4.7 REST OF ASIA PACIFIC 278
14.5 LATIN AMERICA 284
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 285
14.5.2 BRAZIL 290
14.5.2.1 Increased government investments in genomics advancements to drive market 290
14.5.3 MEXICO 296
14.5.3.1 Rising demand for chronic disease treatment to support growth 296
14.5.4 REST OF LATIN AMERICA 301
14.6 MIDDLE EAST & AFRICA 307
14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 307
14.6.2 GCC COUNTRIES 313
14.6.2.1 Saudi Arabia 318
14.6.2.1.1 Growing healthcare expenditure to boost market growth 318
14.6.2.2 UAE 324
14.6.2.2.1 Collaborations to advance genome sequencing and market growth 324
14.6.2.3 Rest of GCC 329
14.6.3 SOUTH AFRICA 334
14.6.3.1 Growing focus on precision medicine to propel market 334
14.6.4 REST OF MIDDLE EAST & AFRICA 339

15 COMPETITIVE LANDSCAPE 345
15.1 OVERVIEW 345
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023–2026 345
15.3 REVENUE ANALYSIS, 2021–2025 348
15.4 MARKET SHARE ANALYSIS, 2025 348
15.5 BRAND COMPARISON 352
15.6 COMPANY VALUATION AND FINANCIAL METRICS 353
15.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 354
15.7.1 STARS 354
15.7.2 EMERGING LEADERS 354
15.7.3 PERVASIVE PLAYERS 354
15.7.4 PARTICIPANTS 354
15.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 356
15.7.5.1 Company footprint 356
15.7.5.2 Region footprint 357
15.7.5.3 Offering footprint 358
15.7.5.4 Function footprint 359
15.7.5.5 Use case footprint 360
15.7.5.6 End user footprint 361
15.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 362
15.8.1 PROGRESSIVE COMPANIES 362
15.8.2 RESPONSIVE COMPANIES 362
15.8.3 DYNAMIC COMPANIES 362
15.8.4 STARTING BLOCKS 362
15.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 364
15.8.5.1 List of startups/SMES 364
15.8.5.2 Competitive benchmarking of Startups/SMEs 365
15.9 COMPETITIVE SCENARIO 365
15.9.1 PRODUCT LAUNCHES & ENHANCEMENTS 365
15.9.2 DEALS 367
15.9.3 EXPANSIONS 369
15.9.4 OTHER DEVELOPMENTS 370

16 COMPANY PROFILES 371
16.1 KEY COMPANIES 371
16.1.1 THERMO FISHER SCIENTIFIC INC. 371
16.1.1.1 Business overview 371
16.1.1.2 Products/Services offered 373
16.1.1.3 Recent developments 375
16.1.1.3.1 Product launches 375
16.1.1.3.2 Deals 375
16.1.1.3.3 Expansions 376
16.1.1.4 MnM view 376
16.1.1.4.1 Key strengths 376
16.1.1.4.2 Strategic choices 376
16.1.1.4.3 Weaknesses and competitive threats 377
16.1.2 ILLUMINA, INC. 378
16.1.2.1 Business overview 378
16.1.2.2 Products/Services offered 379
16.1.2.3 Recent developments 380
16.1.2.3.1 Product launches 380
16.1.2.3.2 Deals 381
16.1.2.3.3 Expansions 384
16.1.2.4 MnM view 384
16.1.2.4.1 Key strengths 384
16.1.2.4.2 Strategic choices 385
16.1.2.4.3 Weaknesses and competitive threats 385
16.1.3 QIAGEN N.V. 386
16.1.3.1 Business overview 386
16.1.3.2 Products/services offered 387
16.1.3.3 Recent developments 389
16.1.3.3.1 Product launches & enhancements 389
16.1.3.3.2 Deals 390
16.1.3.3.3 Other developments 391
16.1.3.3.4 Expansions 392
16.1.3.4 MnM view 392
16.1.3.4.1 Key strengths 392
16.1.3.4.2 Strategic choices 392
16.1.3.4.3 Weaknesses and competitive threats 392
16.1.4 AGILENT TECHNOLOGIES, INC. 393
16.1.4.1 Business overview 393
16.1.4.2 Products/Services offered 394
16.1.4.3 Recent developments 395
16.1.4.3.1 Deals 395
16.1.4.4 MnM view 396
16.1.4.4.1 Key strengths 396
16.1.4.4.2 Strategic choices 396
16.1.4.4.3 Weaknesses and competitive threats 396
16.1.5 F. HOFFMANN-LA ROCHE LTD. 397
16.1.5.1 Business overview 397
16.1.5.2 Products/Services offered 398
16.1.5.3 Recent developments 399
16.1.5.3.1 Product launches 399
16.1.5.3.2 Deals 399
16.1.5.3.3 Other developments 400
16.1.5.4 MnM view 400
16.1.5.4.1 Key strengths 400
16.1.5.4.2 Strategic choices 400
16.1.5.4.3 Weaknesses and competitive threats 400
16.1.6 REVVITY, INC. 401
16.1.6.1 Business overview 401
16.1.6.2 Products/Services offered 402
16.1.6.3 Recent developments 403
16.1.6.3.1 Product launches 403
16.1.6.3.2 Deals 404
16.1.6.3.3 Expansions 405
16.1.7 EUROFINS SCIENTIFIC 406
16.1.7.1 Business overview 406
16.1.7.2 Products/services offered 407
16.1.7.3 Recent developments 408
16.1.7.3.1 Deals 408
16.1.7.3.2 Expansions 409
16.1.8 BGI GENOMICS 410
16.1.8.1 Business overview 410
16.1.8.2 Products/services offered 410
16.1.8.3 Recent developments 412
16.1.8.3.1 Deals 412
16.1.9 WATERS CORPORATION 413
16.1.9.1 Business overview 413
16.1.9.2 Products/services offered 414
16.1.10 DNANEXUS, INC. 415
16.1.10.1 Business overview 415
16.1.10.2 Products/services offered 415
16.1.10.3 Recent developments 416
16.1.10.3.1 Product launches 416
16.1.10.3.2 Deals 417
16.1.10.3.3 Other developments 417
16.1.11 OXFORD NANOPORE TECHNOLOGIES PLC 418
16.1.11.1 Business overview 418
16.1.11.2 Products/Services offered 419
16.1.11.3 Recent developments 420
16.1.11.3.1 Deals 420
16.1.11.3.2 Expansions 421
16.1.12 10X GENOMICS 422
16.1.12.1 Business overview 422
16.1.12.2 Products/Services offered 423
16.1.12.3 Recent developments 424
16.1.12.3.1 Deals 424
16.1.13 PACBIO 426
16.1.13.1 Business overview 426
16.1.13.2 Products/Services offered 427
16.1.13.3 Recent developments 428
16.1.13.3.1 Product launches 428
16.1.13.3.2 Deals 428
16.1.13.3.3 Expansions 429
16.1.14 SIEMENS AG 430
16.1.14.1 Business overview 430
16.1.14.2 Products/Services offered 431
16.1.14.3 Recent developments 432
16.1.14.3.1 Product launches 432
16.1.14.3.2 Deals 433
16.1.14.3.3 Other developments 434
16.1.15 SOPHIA GENETICS 435
16.1.15.1 Business overview 435
16.1.15.2 Products/Services offered 436
16.1.15.3 Recent developments 437
16.1.15.3.1 Product Launches 437
16.1.15.3.2 Deals 437
16.1.15.3.3 Other developments 439
16.1.16 EXCELRA 440
16.1.16.1 Business overview 440
16.1.16.2 Products/Services offered 440
16.1.16.3 Recent developments 441
16.1.16.3.1 Product Enhancement 441
16.1.16.3.2 Deals 442
16.1.17 GENEWIZ (AZENTA LIFE SCIENCES) 443
16.1.17.1 Business overview 443
16.1.17.2 Products/Services offered 444
16.1.17.3 Recent developments 445
16.1.17.3.1 Deals 445
16.1.17.3.2 Other developments 445
16.1.18 ONTOFORCE 446
16.1.18.1 Business overview 446
16.1.18.2 Products/Services offered 446
16.1.18.3 Recent developments 447
16.1.18.3.1 Product launches & enhancements 447
16.1.18.3.2 Deals 448
16.1.19 VELSERA INC. 449
16.1.19.1 Business overview 449
16.1.19.2 Products/Services offered 449
16.1.19.3 Recent developments 450
16.1.19.3.1 Deals 450
16.1.20 SEQERA 451
16.1.20.1 Business overview 451
16.1.20.2 Products/Services offered 451
16.1.20.3 Recent developments 452
16.1.20.3.1 Product launches & enhancement 452
16.1.20.3.2 Deals 453
16.1.20.3.3 Other developments 453
16.2 OTHER PLAYERS 454
16.2.1 DNASTAR 454
16.2.2 FIOS GENOMICS 455
16.2.3 DEEP GENOMICS 456
16.2.4 PSOMAGEN 457
16.2.5 SOURCE BIOSCIENCE 458

17 RESEARCH METHODOLOGY 460
17.1 RESEARCH APPROACH 460
17.1.1 SECONDARY RESEARCH 461
17.1.1.1 Key data from secondary sources 462
17.1.2 PRIMARY RESEARCH 463
17.1.2.1 Key data from primary sources 464
17.1.2.2 Breakdown of primaries 465
17.1.2.3 Insights from primary experts 466
17.2 RESEARCH METHODOLOGY DESIGN 466
17.3 MARKET SIZE ESTIMATION 468
17.4 MARKET BREAKDOWN DATA TRIANGULATION 473
17.5 MARKET SHARE ESTIMATION 475
17.6 STUDY ASSUMPTIONS 475
17.7 RESEARCH LIMITATIONS 476
17.7.1 METHODOLOGY-RELATED LIMITATIONS 476
17.7.2 SCOPE-RELATED LIMITATIONS 476
17.8 RISK ASSESSMENT 476

18 APPENDIX 477
18.1 DISCUSSION GUIDE 477
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 484
18.3 CUSTOMIZATION OPTIONS 486
18.4 RELATED REPORTS 486
18.5 AUTHOR DETAILS 487

ページTOPに戻る

List of Tables/Graphs

FIGURE 1 MARKET SCENARIO 44.
FIGURE 2 GLOBAL BIOINFORMATICS MARKET, 2024–2031 44.
FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BIOINFORMATICS MARKET, 2023–2026 45.
FIGURE 4 DISRUPTIONS INFLUENCING GROWTH OF BIOINFORMATICS MARKET 46.
FIGURE 5 HIGH-GROWTH SEGMENTS IN BIOINFORMATICS MARKET, 2026–2031 47.
FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN BIOINFORMATICS MARKET DURING FORECAST PERIOD 48.
FIGURE 7 INCREASING ADOPTION OF NEXT-GENERATION SEQUENCING TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 49.
FIGURE 8 SOFTWARE ACCOUNTED FOR LARGEST MARKET SHARE.
IN NORTH AMERICA IN 2025 50.
FIGURE 9 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 50.
FIGURE 10 BIOINFORMATICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51.
FIGURE 11 GLOBAL CANCER INCIDENCE, 2008−2030 53.
FIGURE 12 FDA-APPROVED PERSONALIZED MEDICINES, 2015−2024 54.
FIGURE 13 BIOINFORMATICS MARKET: PORTER’S FIVE FORCES ANALYSIS 68.
FIGURE 14 BIOINFORMATICS MARKET: VALUE CHAIN ANALYSIS 72.
FIGURE 15 ECOSYSTEM ANALYSIS 73.
FIGURE 16 REVENUE SHIFT IN BIOINFORMATICS MARKET 79.
FIGURE 17 RECENT FUNDING OF PLAYERS IN BIOINFORMATICS MARKET 80.
FIGURE 18 PATENT PUBLICATION TRENDS IN BIOINFORMATICS MARKET, 2015–2026 93.
FIGURE 19 JURISDICTION AND TOP APPLICANT ANALYSIS FOR BIOINFORMATICS MARKET 93.
FIGURE 20 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) IN BIOINFORMATICS MARKET (JANUARY 2015–JULY 2026) 94.
FIGURE 21 MARKET POTENTIAL OF GENERATIVE AI IN ENHANCING BIOINFORMATICS 98.
FIGURE 22 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 100.
FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS 114.
FIGURE 24 KEY BUYING CRITERIA FOR TOP THREE END USERS 115.
FIGURE 25 NORTH AMERICA: BIOINFORMATICS MARKET SNAPSHOT 188.
FIGURE 26 ASIA PACIFIC: BIOINFORMATICS MARKET SNAPSHOT 246.
FIGURE 27 REVENUE ANALYSIS OF TOP LISTED/PUBLIC PLAYERS, 2021–2025 (USD MILLION) 348.
FIGURE 28 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025 349.
FIGURE 29 BRAND COMPARISON 352.
FIGURE 30 EV/EBITDA OF KEY VENDORS 353.
FIGURE 31 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK BETA.
OF KEY VENDORS 353.
FIGURE 32 COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 355.
FIGURE 33 BIOINFORMATICS MARKET: COMPANY FOOTPRINT 356.
FIGURE 34 COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 363.
FIGURE 35 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 372.
FIGURE 36 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 379.
FIGURE 37 QIAGEN N.V.: COMPANY SNAPSHOT (2025) 387.
FIGURE 38 GILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 394.
FIGURE 39 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 398.
FIGURE 40 REVVITY, INC.: COMPANY SNAPSHOT (2025) 402.
FIGURE 41 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025) 407.
FIGURE 42 WATERS CORPORATION: COMPANY SNAPSHOT (2025) 414.
FIGURE 43 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2025) 419.
FIGURE 44 10X GENOMICS: COMPANY SNAPSHOT (2025) 423.
FIGURE 45 PACBIO: COMPANY SNAPSHOT (2025) 427.
FIGURE 46 SIEMENS AG: COMPANY SNAPSHOT (2025) 431.
FIGURE 47 SOPHIA GENETICS: COMPANY SNAPSHOT (2025) 436.
FIGURE 48 AZENTA INC.: COMPANY SNAPSHOT (2025) 444.
FIGURE 49 RESEARCH DESIGN 460.
FIGURE 50 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,.
DESIGNATION, AND REGION 465.
FIGURE 51 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 467.
FIGURE 52 BOTTOM-UP APPROACH 468.
FIGURE 53 TOP-DOWN APPROACH 469.
FIGURE 54 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF BIOINFORMATICS MARKET 470.
FIGURE 55 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 471.
FIGURE 56 DATA TRIANGULATION METHODOLOGY 474.
TABLE 1 EXCHANGE RATES FOR CONVERSION TO USD 41.
TABLE 2 ASIA PACIFIC: R&D INVESTMENT BY PHARMACEUTICAL.
AND BIOTECHNOLOGY COMPANIES 54.
TABLE 3 PUBLIC AND PRIVATE-SECTOR FUNDING FOR BIOINFORMATICS.
AND RELATED FIELDS 56.
TABLE 4 BIOINFORMATICS MARKET: PORTER’S FIVE FORCES 68.
TABLE 5 BIOINFORMATICS MARKET: ROLE IN ECOSYSTEM 74.
TABLE 6 INDICATIVE PRICING IN BIOINFORMATICS MARKET, BY OFFERING (2025) 75.
TABLE 7 INDICATIVE PRICING OF SOFTWARE (NICHE POINT SOLUTIONS), BY REGION (2025) 76.
TABLE 8 BIOINFORMATICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 77.
TABLE 9 CASE 1: FASTER WORKFLOWS, COST-EFFICIENCY, AND SIMPLIFIED INFRASTRUCTURE 80.
TABLE 10 CASE STUDY 2: COMPREHENSIVE CLINICAL EXOME ANALYSIS TO SUPPORT DIVERSE APPLICATIONS AT HENRY FORD HEALTH 81.
TABLE 11 CASE STUDY 2: CHAMPIONS ONCOLOGY SCALES MULTIOMICS ANALYSIS WITH SEQERA TO ACCELERATE CANCER THERAPY DEVELOPMENT 81.
TABLE 12 US ADJUSTED RECIPROCAL TARIFF RATES 83.
TABLE 13 COUNTRY 83.
TABLE 14 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR.
BIOINFORMATICS MARKET 93.
TABLE 15 BIOINFORMATICS MARKET: KEY PATENTS/PATENT APPLICATIONS 95.
TABLE 16 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 105.
TABLE 17 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 106.
TABLE 18 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 107.
TABLE 19 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 107.
TABLE 20 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,.
AND OTHER ORGANIZATIONS 108.
TABLE 21 REGULATORY SCENARIO IN NORTH AMERICA 108.
TABLE 22 REGULATORY SCENARIO IN EUROPE 109.
TABLE 23 REGULATORY SCENARIO IN ASIA PACIFIC 110.
TABLE 24 REGULATORY SCENARIO IN LATIN AMERICA 110.
TABLE 25 REGULATORY SCENARIO IN MIDDLE EAST & AFRICA 111.
TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE.
END USERS (%) 115.
TABLE 27 KEY BUYING CRITERIA FOR TOP THREE END USERS 116.
TABLE 28 UNMET NEEDS IN BIOINFORMATICS MARKET 118.
TABLE 29 END USER EXPECTATIONS IN BIOINFORMATICS MARKET 119.
TABLE 30 BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 122.
TABLE 31 BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 123.
TABLE 32 BIOINFORMATICS MARKET FOR SOFTWARE, BY REGION,.
2024–2031(USD MILLION) 123.
TABLE 33 NICHE POINT SOLUTIONS OFFERED BY KEY MARKET PLAYERS 124.
TABLE 34 BIOINFORMATICS MARKET FOR NICHE POINT SOLUTIONS, BY REGION,.
2024–2031(USD MILLION) 125.
TABLE 35 BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS,.
BY TYPE, 2024–2031 (USD MILLION) 126.
TABLE 36 BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS,.
BY REGION, 2024–2031 (USD MILLION) 126.
TABLE 37 GENERALIZED KNOWLEDGE MANAGEMENT TOOLS OFFERED.
BY KEY MARKET PLAYERS 127.
TABLE 38 BIOINFORMATICS MARKET FOR GENERALIZED KNOWLEDGE MANAGEMENT TOOLS, BY REGION, 2024–2031 (USD MILLION) 127.
TABLE 39 SPECIALIZED KNOWLEDGE MANAGEMENT TOOLS OFFERED.
BY KEY MARKET PLAYERS 128.
TABLE 40 BIOINFORMATICS MARKET FOR SPECIALIZED KNOWLEDGE MANAGEMENT TOOLS, BY REGION, 2024–2031 (USD MILLION) 129.
TABLE 41 BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE,.
2024–2031 (USD MILLION) 130.
TABLE 42 BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY REGION,.
2024–2031 (USD MILLION) 130.
TABLE 43 GENOMIC SOLUTIONS OFFERED BY KEY MARKET PLAYERS 131.
TABLE 44 BIOINFORMATICS MARKET FOR GENOMIC SOLUTIONS, BY REGION,.
2024–2031 (USD MILLION) 132.
TABLE 45 MULTIOMICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS 133.
TABLE 46 BIOINFORMATICS MARKET FOR MULTIOMICS SOLUTIONS, BY REGION,.
2024–2031 (USD MILLION) 133.
TABLE 47 CHEMOINFORMATICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS 134.
TABLE 48 BIOINFORMATICS MARKET FOR CHEMOINFORMATICS SOLUTIONS,.
BY REGION, 2024–2031 (USD MILLION) 134.
TABLE 49 PROTEOMICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS 135.
TABLE 50 BIOINFORMATICS MARKET FOR PROTEOMICS SOLUTIONS, BY REGION,.
2024–2031 (USD MILLION) 136.
TABLE 51 TRANSCRIPTOMICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS 137.
TABLE 52 BIOINFORMATICS MARKET FOR TRANSCRIPTOMICS SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 137.
TABLE 53 METABOLOMICS SOLUTIONS OFFERED BY KEY MARKET PLAYERS 138.
TABLE 54 BIOINFORMATICS MARKET FOR METABOLOMICS SOLUTIONS, BY REGION,.
2024–2031 (USD MILLION) 138.
TABLE 55 OTHER END-TO-END SOLUTIONS OFFERED BY KEY MARKET PLAYERS 139.
TABLE 56 BIOINFORMATICS MARKET FOR OTHER END-TO-END SOLUTIONS, BY REGION, 2024–2031 (USD MILLION) 139.
TABLE 57 BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 140.
TABLE 58 BIOINFORMATICS MARKET FOR SERVICES, BY REGION,.
2024–2031 (USD MILLION) 140.
TABLE 59 SEQUENCING & DATA GENERATION SERVICES OFFERED BY KEY MARKET PLAYERS 141.
TABLE 60 BIOINFORMATICS MARKET FOR SEQUENCING & DATA GENERATION SERVICES,.
BY REGION, 2024–2031 (USD MILLION) 142.
TABLE 61 DATA ANALYSIS & INTERPRETATION SERVICES OFFERED BY KEY MARKET PLAYERS 143.
TABLE 62 BIOINFORMATICS MARKET FOR DATA ANALYSIS & INTERPRETATION, BY REGION, 2024–2031 (USD MILLION) 143.
TABLE 63 DRUG DISCOVERY & TARGET IDENTIFICATION OFFERED BY KEY MARKET PLAYERS 144.
TABLE 64 BIOINFORMATICS MARKET FOR DRUG DISCOVERY & TARGET IDENTIFICATION,.
BY REGION, 2024–2031 (USD MILLION) 144.
TABLE 65 DATABASE & DATA MANAGEMENT SERVICES OFFERED BY KEY MARKET PLAYERS 145.
TABLE 66 BIOINFORMATICS MARKET FOR DATABASE & DATA MANAGEMENT, BY REGION, 2024–2031 (USD MILLION) 145.
TABLE 67 CLOUD & MANAGED BIOINFORMATICS SERVICES OFFERED.
BY KEY MARKET PLAYERS 146.
TABLE 68 BIOINFORMATICS MARKET FOR CLOUD & MANAGED BIOINFORMATICS,.
BY REGION, 2024–2031 (USD MILLION) 146.
TABLE 69 CONSULTING & CUSTOM BIOINFORMATICS DEVELOPMENT SERVICES OFFERED.
BY KEY MARKET PLAYERS 147.
TABLE 70 BIOINFORMATICS MARKET FOR CONSULTING & CUSTOM BIOINFORMATICS DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 148.
TABLE 71 OTHER BIOINFORMATICS SERVICES OFFERED BY KEY MARKET PLAYERS 148.
TABLE 72 BIOINFORMATICS MARKET FOR OTHER SERVICES, BY REGION,.
2024–2031 (USD MILLION) 149.
TABLE 73 BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 151.
TABLE 74 BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE,.
2024–2031 (USD MILLION) 152.
TABLE 75 BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY REGION,.
2024–2031 (USD MILLION) 152.
TABLE 76 BIOINFORMATICS MARKET FOR SEQUENCE ANALYSIS, BY REGION,.
2024–2031 (USD MILLION) 153.
TABLE 77 BIOINFORMATICS MARKET FOR VARIANT ANALYSIS, BY REGION,.
2024–2031 (USD MILLION) 154.
TABLE 78 BIOINFORMATICS MARKET FOR GENE EXPRESSION ANALYSIS, BY REGION,.
2024–2031 (USD MILLION) 154.
TABLE 79 BIOINFORMATICS MARKET FOR OTHER DATA ANALYSIS FUNCTIONS, BY REGION, 2024–2031 (USD MILLION) 155.
TABLE 80 BIOINFORMATICS MARKET FOR STRUCTURAL & FUNCTIONAL ANALYSIS,.
BY REGION, 2024–2031 (USD MILLION) 156.
TABLE 81 BIOINFORMATICS MARKET FOR MULTIOMICS INTEGRATION, BY REGION,.
2024–2031 (USD MILLION) 157.
TABLE 82 BIOINFORMATICS MARKET FOR CLINICAL INTERPRETATION, BY REGION,.
2024–2031 (USD MILLION) 158.
TABLE 83 BIOINFORMATICS MARKET FOR DATA VISUALIZATION & REPORTING, BY REGION, 2024–2031 (USD MILLION) 159.
TABLE 84 BIOINFORMATICS MARKET FOR OTHER FUNCTIONS, BY REGION,.
2024–2031 (USD MILLION) 160.
TABLE 85 BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 162.
TABLE 86 BIOINFORMATICS MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024–2031 (USD MILLION) 163.
TABLE 87 BIOINFORMATICS MARKET FOR PRECISION MEDICINE, BY REGION,.
2024–2031 (USD MILLION) 164.
TABLE 88 BIOINFORMATICS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION,.
2024–2031 (USD MILLION) 165.
TABLE 89 BIOINFORMATICS MARKET FOR BIOMARKER DISCOVERY, BY REGION,.
2024–2031 (USD MILLION) 166.
TABLE 90 BIOINFORMATICS MARKET FOR RESEARCH & ACADEMIC APPLICATIONS,.
BY REGION, 2024–2031 (USD MILLION) 167.
TABLE 91 BIOINFORMATICS MARKET FOR OTHER USE CASES, BY REGION,.
2024–2031 (USD MILLION) 168.
TABLE 92 BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 170.
TABLE 93 BIOINFORMATICS MARKET FOR MEDICAL BIOTECHNOLOGY, BY REGION,.
2024–2031 (USD MILLION) 171.
TABLE 94 BIOINFORMATICS MARKET FOR ANIMAL BIOTECHNOLOGY, BY REGION,.
2024–2031 (USD MILLION) 172.
TABLE 95 BIOINFORMATICS MARKET FOR PLANT BIOTECHNOLOGY, BY REGION,.
2024–2031 (USD MILLION) 173.
TABLE 96 BIOINFORMATICS MARKET FOR ENVIRONMENTAL BIOTECHNOLOGY, BY REGION, 2024–2031 (USD MILLION) 174.
TABLE 97 BIOINFORMATICS MARKET FOR FORENSIC BIOTECHNOLOGY, BY REGION,.
2024–2031 (USD MILLION) 175.
TABLE 98 BIOINFORMATICS MARKET FOR OTHER SECTORS, BY REGION,.
2024–2031 (USD MILLION) 176.
TABLE 99 BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 178.
TABLE 100 BIOINFORMATICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 179.
TABLE 101 BIOINFORMATICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 180.
TABLE 102 BIOINFORMATICS MARKET FOR HOSPITALS & CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 182.
TABLE 103 BIOINFORMATICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 183.
TABLE 104 BIOINFORMATICS MARKET FOR GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 184.
TABLE 105 BIOINFORMATICS MARKET FOR OTHER END USERS, BY REGION,.
2024–2031 (USD MILLION) 185.
TABLE 106 BIOINFORMATICS MARKET, BY REGION, 2024–2031 (USD MILLION) 187.
TABLE 107 NORTH AMERICA: BIOINFORMATICS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 189.
TABLE 108 NORTH AMERICA: BIOINFORMATICS MARKET, BY OFFERING,.
2024–2031 (USD MILLION) 189.
TABLE 109 NORTH AMERICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 190.
TABLE 110 NORTH AMERICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 190.
TABLE 111 NORTH AMERICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS,.
BY TYPE, 2024–2031 (USD MILLION) 191.
TABLE 112 NORTH AMERICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 191.
TABLE 113 NORTH AMERICA: BIOINFORMATICS MARKET, BY FUNCTION,.
2024–2031 (USD MILLION) 192.
TABLE 114 NORTH AMERICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS,.
BY TYPE, 2024–2031 (USD MILLION) 192.
TABLE 115 NORTH AMERICA: BIOINFORMATICS MARKET, BY USE CASE,.
2024–2031 (USD MILLION) 193.
TABLE 116 NORTH AMERICA: BIOINFORMATICS MARKET, BY SECTOR,.
2024–2031 (USD MILLION) 193.
TABLE 117 NORTH AMERICA: BIOINFORMATICS MARKET, BY END USER,.
2024–2031 (USD MILLION) 194.
TABLE 118 US: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 195.
TABLE 119 US: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 196.
TABLE 120 US: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 196.
TABLE 121 US: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE,.
2024–2031 (USD MILLION) 197.
TABLE 122 US: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 197.
TABLE 123 US: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 198.
TABLE 124 US: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE,.
2024–2031 (USD MILLION) 198.
TABLE 125 US: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 199.
TABLE 126 US: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 199.
TABLE 127 US: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 200.
TABLE 128 CANADA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 201.
TABLE 129 CANADA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 202.
TABLE 130 CANADA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS,.
BY TYPE, 2024–2031 (USD MILLION) 202.
TABLE 131 CANADA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS,.
BY TYPE, 2024–2031 (USD MILLION) 203.
TABLE 132 CANADA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 203.
TABLE 133 CANADA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 204.
TABLE 134 CANADA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE,.
2024–2031 (USD MILLION) 204.
TABLE 135 CANADA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 205.
TABLE 136 CANADA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 205.
TABLE 137 CANADA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 206.
TABLE 138 EUROPE: BIOINFORMATICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 207.
TABLE 139 EUROPE: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 207.
TABLE 140 EUROPE: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 208.
TABLE 141 EUROPE: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS,.
BY TYPE, 2024–2031 (USD MILLION) 208.
TABLE 142 EUROPE: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS,.
BY TYPE, 2024–2031 (USD MILLION) 209.
TABLE 143 EUROPE: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 209.
TABLE 144 EUROPE: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 210.
TABLE 145 EUROPE: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE,.
2024–2031 (USD MILLION) 210.
TABLE 146 EUROPE: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 211.
TABLE 147 EUROPE: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 211.
TABLE 148 EUROPE: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 212.
TABLE 149 GERMANY: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 213.
TABLE 150 GERMANY: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 214.
TABLE 151 GERMANY: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 214.
TABLE 152 GERMANY: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 215.
TABLE 153 GERMANY: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 215.
TABLE 154 GERMANY: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 216.
TABLE 155 GERMANY: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE,.
2024–2031 (USD MILLION) 216.
TABLE 156 GERMANY: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 217.
TABLE 157 GERMANY: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 217.
TABLE 158 GERMANY: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 218.
TABLE 159 UK: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 219.
TABLE 160 UK: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 219.
TABLE 161 UK: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 220.
TABLE 162 UK: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE,.
2024–2031 (USD MILLION) 220.
TABLE 163 UK: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 221.
TABLE 164 UK: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 221.
TABLE 165 UK: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE,.
2024–2031 (USD MILLION) 222.
TABLE 166 UK: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 222.
TABLE 167 UK: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 223.
TABLE 168 UK: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 223.
TABLE 169 FRANCE: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 225.
TABLE 170 FRANCE: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 225.
TABLE 171 FRANCE: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS,.
BY TYPE, 2024–2031 (USD MILLION) 225.
TABLE 172 FRANCE: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 226.
TABLE 173 FRANCE: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 226.
TABLE 174 FRANCE: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 227.
TABLE 175 FRANCE: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE,.
2024–2031 (USD MILLION) 227.
TABLE 176 FRANCE: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 228.
TABLE 177 FRANCE: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 228.
TABLE 178 FRANCE: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 229.
TABLE 179 ITALY: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 230.
TABLE 180 ITALY: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 230.
TABLE 181 ITALY: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS,.
BY TYPE, 2024–2031 (USD MILLION) 231.
TABLE 182 ITALY: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE,.
2024–2031 (USD MILLION) 231.
TABLE 183 ITALY: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 232.
TABLE 184 ITALY: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 232.
TABLE 185 ITALY: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE,.
2024–2031 (USD MILLION) 233.
TABLE 186 ITALY: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 233.
TABLE 187 ITALY: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 234.
TABLE 188 ITALY: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 234.
TABLE 189 SPAIN: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 235.
TABLE 190 SPAIN: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 236.
TABLE 191 SPAIN: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS,.
BY TYPE, 2024–2031 (USD MILLION) 236.
TABLE 192 SPAIN: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE,.
2024–2031 (USD MILLION) 236.
TABLE 193 SPAIN: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 237.
TABLE 194 SPAIN: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 237.
TABLE 195 SPAIN: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE,.
2024–2031 (USD MILLION) 238.
TABLE 196 SPAIN: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 238.
TABLE 197 SPAIN: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 239.
TABLE 198 SPAIN: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 239.
TABLE 199 REST OF EUROPE: BIOINFORMATICS MARKET, BY OFFERING,.
2024–2031 (USD MILLION) 240.
TABLE 200 REST OF EUROPE: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 241.
TABLE 201 REST OF EUROPE: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 241.
TABLE 202 REST OF EUROPE: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS,.
BY TYPE, 2024–2031 (USD MILLION) 242.
TABLE 203 REST OF EUROPE: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 242.
TABLE 204 REST OF EUROPE: BIOINFORMATICS MARKET, BY FUNCTION,.
2024–2031 (USD MILLION) 243.
TABLE 205 REST OF EUROPE: BIOINFORMATICS MARKET FOR DATA ANALYSIS,.
BY TYPE, 2024–2031 (USD MILLION) 243.
TABLE 206 REST OF EUROPE: BIOINFORMATICS MARKET, BY USE CASE,.
2024–2031 (USD MILLION) 244.
TABLE 207 REST OF EUROPE: BIOINFORMATICS MARKET, BY SECTOR,.
2024–2031 (USD MILLION) 244.
TABLE 208 REST OF EUROPE: BIOINFORMATICS MARKET, BY END USER,.
2024–2031 (USD MILLION) 245.
TABLE 209 ASIA PACIFIC: BIOINFORMATICS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 247.
TABLE 210 ASIA PACIFIC: BIOINFORMATICS MARKET, BY OFFERING,.
2024–2031 (USD MILLION) 247.
TABLE 211 ASIA PACIFIC: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 247.
TABLE 212 ASIA PACIFIC: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 248.
TABLE 213 ASIA PACIFIC: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 248.
TABLE 214 ASIA PACIFIC: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 249.
TABLE 215 ASIA PACIFIC: BIOINFORMATICS MARKET, BY FUNCTION,.
2024–2031 (USD MILLION) 249.
TABLE 216 ASIA PACIFIC: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE,.
2024–2031 (USD MILLION) 250.
TABLE 217 ASIA PACIFIC: BIOINFORMATICS MARKET, BY USE CASE,.
2024–2031 (USD MILLION) 250.
TABLE 218 ASIA PACIFIC: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 251.
TABLE 219 ASIA PACIFIC: BIOINFORMATICS MARKET, BY END USER,.
2024–2031 (USD MILLION) 251.
TABLE 220 CHINA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 253.
TABLE 221 CHINA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 253.
TABLE 222 CHINA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS,.
BY TYPE, 2024–2031 (USD MILLION) 253.
TABLE 223 CHINA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS,.
BY TYPE, 2024–2031 (USD MILLION) 254.
TABLE 224 CHINA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 254.
TABLE 225 CHINA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 255.
TABLE 226 CHINA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE,.
2024–2031 (USD MILLION) 255.
TABLE 227 CHINA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 256.
TABLE 228 CHINA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 256.
TABLE 229 CHINA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 257.
TABLE 230 JAPAN: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 258.
TABLE 231 JAPAN: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 258.
TABLE 232 JAPAN: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS,.
BY TYPE, 2024–2031 (USD MILLION) 259.
TABLE 233 JAPAN: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE,.
2024–2031 (USD MILLION) 259.
TABLE 234 JAPAN: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 260.
TABLE 235 JAPAN: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 260.
TABLE 236 JAPAN: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE,.
2024–2031 (USD MILLION) 261.
TABLE 237 JAPAN: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 261.
TABLE 238 JAPAN: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 262.
TABLE 239 JAPAN: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 262.
TABLE 240 INDIA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 263.
TABLE 241 INDIA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 264.
TABLE 242 INDIA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS,.
BY TYPE, 2024–2031 (USD MILLION) 264.
TABLE 243 INDIA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE,.
2024–2031 (USD MILLION) 264.
TABLE 244 INDIA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 265.
TABLE 245 INDIA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 265.
TABLE 246 INDIA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE,.
2024–2031 (USD MILLION) 266.
TABLE 247 INDIA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 266.
TABLE 248 INDIA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 267.
TABLE 249 INDIA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 267.
TABLE 250 AUSTRALIA: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 268.
TABLE 251 AUSTRALIA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 269.
TABLE 252 AUSTRALIA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 269.
TABLE 253 AUSTRALIA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS,.
BY TYPE, 2024–2031 (USD MILLION) 270.
TABLE 254 AUSTRALIA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 270.
TABLE 255 AUSTRALIA: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 271.
TABLE 256 AUSTRALIA: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE,.
2024–2031 (USD MILLION) 271.
TABLE 257 AUSTRALIA: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 272.
TABLE 258 AUSTRALIA: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 272.
TABLE 259 AUSTRALIA: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 273.
TABLE 260 SOUTH KOREA: BIOINFORMATICS MARKET, BY OFFERING,.
2024–2031 (USD MILLION) 274.
TABLE 261 SOUTH KOREA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 274.
TABLE 262 SOUTH KOREA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 275.
TABLE 263 SOUTH KOREA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 275.
TABLE 264 SOUTH KOREA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 276.
TABLE 265 SOUTH KOREA: BIOINFORMATICS MARKET, BY FUNCTION,.
2024–2031 (USD MILLION) 276.
TABLE 266 SOUTH KOREA: BIOINFORMATICS MARKET FOR DATA ANALYSIS,.
BY TYPE, 2024–2031 (USD MILLION) 277.
TABLE 267 SOUTH KOREA: BIOINFORMATICS MARKET, BY USE CASE,.
2024–2031 (USD MILLION) 277.
TABLE 268 SOUTH KOREA: BIOINFORMATICS MARKET, BY SECTOR,.
2024–2031 (USD MILLION) 278.
TABLE 269 SOUTH KOREA: BIOINFORMATICS MARKET, BY END USER,.
2024–2031 (USD MILLION) 278.
TABLE 270 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY OFFERING,.
2024–2031 (USD MILLION) 279.
TABLE 271 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 280.
TABLE 272 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 280.
TABLE 273 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 281.
TABLE 274 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 281.
TABLE 275 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY FUNCTION,.
2024–2031 (USD MILLION) 282.
TABLE 276 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET FOR DATA ANALYSIS,.
BY TYPE, 2024–2031 (USD MILLION) 282.
TABLE 277 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY USE CASE,.
2024–2031 (USD MILLION) 283.
TABLE 278 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY SECTOR,.
2024–2031 (USD MILLION) 283.
TABLE 279 REST OF ASIA PACIFIC: BIOINFORMATICS MARKET, BY END USER,.
2024–2031 (USD MILLION) 284.
TABLE 280 LATIN AMERICA: BIOINFORMATICS MARKET, BY COUNTRY,.
2024–2031 (USD MILLION) 285.
TABLE 281 LATIN AMERICA: BIOINFORMATICS MARKET, BY OFFERING,.
2024–2031 (USD MILLION) 286.
TABLE 282 LATIN AMERICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 286.
TABLE 283 LATIN AMERICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 286.
TABLE 284 LATIN AMERICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS,.
BY TYPE, 2024–2031 (USD MILLION) 287.
TABLE 285 LATIN AMERICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 287.
TABLE 286 LATIN AMERICA: BIOINFORMATICS MARKET, BY FUNCTION,.
2024–2031 (USD MILLION) 288.
TABLE 287 LATIN AMERICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS,.
BY TYPE, 2024–2031 (USD MILLION) 288.
TABLE 288 LATIN AMERICA: BIOINFORMATICS MARKET, BY USE CASE,.
2024–2031 (USD MILLION) 289.
TABLE 289 LATIN AMERICA: BIOINFORMATICS MARKET, BY SECTOR,.
2024–2031 (USD MILLION) 289.
TABLE 290 LATIN AMERICA: BIOINFORMATICS MARKET, BY END USER,.
2024–2031 (USD MILLION) 290.
TABLE 291 BRAZIL: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 291.
TABLE 292 BRAZIL: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 291.
TABLE 293 BRAZIL: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS,.
BY TYPE, 2024–2031 (USD MILLION) 292.
TABLE 294 BRAZIL: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE,.
2024–2031 (USD MILLION) 292.
TABLE 295 BRAZIL: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 293.
TABLE 296 BRAZIL: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 293.
TABLE 297 BRAZIL: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE,.
2024–2031 (USD MILLION) 294.
TABLE 298 BRAZIL: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 294.
TABLE 299 BRAZIL: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 295.
TABLE 300 BRAZIL: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 295.
TABLE 301 MEXICO: BIOINFORMATICS MARKET, BY OFFERING, 2024–2031 (USD MILLION) 297.
TABLE 302 MEXICO: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE,.
2024–2031 (USD MILLION) 297.
TABLE 303 MEXICO: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS,.
BY TYPE, 2024–2031 (USD MILLION) 297.
TABLE 304 MEXICO: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 298.
TABLE 305 MEXICO: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE,.
2024–2031 (USD MILLION) 298.
TABLE 306 MEXICO: BIOINFORMATICS MARKET, BY FUNCTION, 2024–2031 (USD MILLION) 299.
TABLE 307 MEXICO: BIOINFORMATICS MARKET FOR DATA ANALYSIS, BY TYPE,.
2024–2031 (USD MILLION) 299.
TABLE 308 MEXICO: BIOINFORMATICS MARKET, BY USE CASE, 2024–2031 (USD MILLION) 300.
TABLE 309 MEXICO: BIOINFORMATICS MARKET, BY SECTOR, 2024–2031 (USD MILLION) 300.
TABLE 310 MEXICO: BIOINFORMATICS MARKET, BY END USER, 2024–2031 (USD MILLION) 301.
TABLE 311 REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY OFFERING,.
2024–2031 (USD MILLION) 302.
TABLE 312 REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR SOFTWARE, BY TYPE, 2024–2031 (USD MILLION) 302.
TABLE 313 REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR KNOWLEDGE MANAGEMENT TOOLS, BY TYPE, 2024–2031 (USD MILLION) 303.
TABLE 314 REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR END-TO-END SOLUTIONS, BY TYPE, 2024–2031 (USD MILLION) 303.
TABLE 315 REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 304.
TABLE 316 REST OF LATIN AMERICA: BIOINFORMATICS MARKET, BY FUNCTION,.
2024–2031 (USD MILLION) 304.
TABLE 317 REST OF LATIN AMERICA: BIOINFORMATICS MARKET FOR DATA ANALYSIS,.
BY TYPE, 2024–2031 (USD MILLION) 305.